Skip to content
All Sections
Subscribe Now
61°F
Monday, September 30th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
61°F
Monday, September 30th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Latest Trump news
Man hit, killed by fire engine
Affordable senior housing opens
Westbrook Academy reopens
High School Football
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Axsome Therapeutics, Inc.
< Previous
1
2
Next >
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
September 24, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
September 04, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Participate in Investor Conferences in September
August 27, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
August 21, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
July 11, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
June 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
June 04, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
June 03, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 30, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
May 29, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
May 28, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 06, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
May 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
April 10, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
April 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
March 19, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 20, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
January 23, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
January 04, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
December 11, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
December 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
November 22, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close